CD33 and Alzheimer disease: Genetic deletion of CD33 markedly enhanced the microglial phagocytosis of Aβ aggregates in vitro (Griciuc et al., 2013; Wißfeld et al., 2021), and reduced Aβ deposition in vivo leading to improved cognitive functions in mouse models of AD (Griciuc et al., 2013, 2019).